Shire PLC: A new phase III studying SPD602 vs Exjade from Novartis

NEUTRAL, Fair Value  2350p (-3%)

News published on August Monday 26, 2013
Share on

Last week, Shire posted a new phase II trial studying SPD602 (its own iron chelator) with Exjade (deferasirox) from Novartis for the treatment of chronic transfusional iron overload in subjects with beta thalassemia. At this point, we factor a 50% probability of success for this compound which targets a market historically controlled by Novartis with Desferal and Exjade (850mUSD in 2012).

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities